Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11312768 Signature of TL1A (TNFSF15) signaling pathway

Patent 11312768 was granted and assigned to Cedars-Sinai Medical Center on April, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Cedars-Sinai Medical Center

0

Current Assignee

Cedars-Sinai Medical Center

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Stephan R. Targan0

Kathrin S. Michelsen0

Date of Patent

April 26, 2022

0

Patent Application Number

163881010

Date Filed

April 18, 2019

0

Patent Citations

US Patent 10316083 Signature of TL1A (TNFSF15) signaling pathway

US Patent 10322174 Neutralizing anti-TL1A monoclonal antibodies

US Patent 10626180 Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease

Patent Primary Examiner

Bridget E Bunner

0

CPC Code

0

0

0

0

0

0

0

0

...

The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TL17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11312768 Signature of TL1A (TNFSF15) signaling pathway

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool